 Shares of the South San Francisco-based micro-cap biopharma Tempest Therapeutics Inc. NASDAQ: TPST were soaring Monday for a second consecutive trading session on above-average volume. Tempests Wild Ride: Tempest, which recently began trading on the Nasdaq through a reverse merger with Millendo Therapeutics, is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. 